Author/Authors :
Athanasios Papatheodorou، نويسنده , , Panagiota Latsi، نويسنده , , Christina Vrettou، نويسنده , , Aikaterini Dimakou، نويسنده , , Alexia Chroneou، نويسنده , , Periklis Makrythanasis، نويسنده , , Marios Kaliakatsos، نويسنده , , Dora Orfanidou، نويسنده , , Charis Roussos، نويسنده , , Emmanuel Kanavakis، نويسنده , , Maria Tzetis، نويسنده ,
Abstract :
Objectives:
Polymorphisms in promoter region of TNF-α gene were shown to interfere with the transcriptional activity of the gene resulting in the production of different levels of TNF-α product suggesting their involvement in susceptibility or severity of many inflammatory diseases. We set up a case–control study consisting of 117 COPD (Chronic Obstructive Pulmonary Disease), 62 DB (bronchiectasis) patients and two control groups (109 smokers without COPD-healthy smokers control group and 212 general population subjects) to evaluate involvement of TNF-α gene polymorphisms in the abovementioned diseases in a homogeneous population.
Methods:
The novel methodology of the NanoChip™ Molecular Biology Workstation (MBW Nanogen http://www.nanogen.com) was employed to genotype the 5 promoter SNPs.
Results and conclusions:
Genotype frequencies of the 5 SNPs showed no significant difference between the COPD and DB patient groups and the healthy smokers group. Statistical difference (p = 0.043) was only revealed between the haplotype frequencies in COPD patients compared to the general population control group. The NanoChip™ MBW is an accurate method for SNP screening.
Keywords :
Proteases , Myocardial ischemia , Troponin T , Coronary arteriosclerosis